ADH5 and pulmonary embolism: These studies provide compelling evidence that optimizing GSNO through exogenous GSNO treatment or inhibition of GSNOR activity offers protection against SP-S1-induced multi-mechanistic diseases associated with COVID-19, including cytokine storm, hypercoagulopathy, pulmonary embolism, and inflammatory and vascular lung diseases.